BGI, Novo Nordisk Partner to Create Collaborative Framework

Mar 03, 2012

NEW YORK (GenomeWeb News) – BGI and Novo Nordisk today announced a collaboration to create a "global collaboration framework."

The two firms provided few details about the agreement but said that it would create an opportunity for them to "accelerate their growth, execute their global partnering strategy and support disease research and development efforts." BGI will contribute its next-generation sequencing platforms and bioinformatics capabilities, and Novo Nordisk will contribute its drug development expertise.

Financial and other terms were not disclosed.

Last month BGI officially opened its European Genome Research Center in Denmark, where Novo Nordisk is heaquartered, and in a statement today Ning Li, director of BGI Europe, said it would provide "an excellent platform for us and our collaborators."

Filed under

Clinical Sequencing

Next-Generation Sequencing

BGI

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.